Clinical Trials Logo
  1. Home
  2. Fungemia
  3. NCT03876990

Clinical and Medico-economic Evaluation of a Rapid Test (ePlex-BCID®, GenMark) for the Diagnosis of Bacteremia and Fungemia. — HEMOFAST  

Fungemia Clinical Trial

Official title:
Clinical and Medico-economic Evaluation of a Rapid Test (ePlex-BCID®, GenMark) for the Diagnosis of Bacteremia or Fungemia From Positive Blood Culture Bottles, Combining Fast Identification of Bacteria and Fungi and Evaluation of Bacterial Resistance to First Line Antibiotics.

Clinical Trial Summary

This study evaluates the clinical benefit of a rapid test for fast diagnosis of bacteremia and fungemia from positive blood cultures in case of sepsis. This assay enables rapid identification of bacteria and fungi and allows to evaluate bacterial resistance to first line antibiotics. The clinical and medico-economic impact of this assay used in addition to the current diagnosis strategy (half of the patients) will be compared to the current diagnostic strategy alone (other half of the patient).

Clinical Trial Description

Bacteremia and fungemia are severe complications, sometimes life-threatening, of every sepsis. During septicemia, every hour matters to start an appropriate antibiotic or antifungal treatment as every hour of delay is associated to higher death rate. The rapid multiplex PCR assay that is evaluated in this study allows to identify in 60 to 90 minutes, the bacteria or fungi that is present in the positive blood culture bottles and to identify resistance markers to first line antibiotics that are used to treat sepsis. This strategy allows quicker adaptation of antibacterial or antifungal treatment based on the species of the bacteria or fungi identified and on the results of the resistance markers compared to current diagnosis strategy of bacteremia or fungemia. This quicker adaptation could lead to improved survival rate, reduced complications of sepsis, reduced hospital stay length and could reduce the use of large spectrum antibiotics. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03876990
Study type Interventional
Source University Hospital, Grenoble
Contact
Status Completed
Phase N/A
Start date June 20, 2019
Completion date February 19, 2021
View Details
See also
  Status Clinical Trial Phase
Completed NCT00177788 - Voriconazole as Prophylaxis for Liver Transplant Recipients N/A
Completed NCT00027248 - Safety and Efficacy of MBI 226 for the Prevention of Central Venous Catheter-Related Bloodstream Infections Phase 3
Completed NCT01359891 - Clinical Evaluation of Novel Biomarkers in Patients With Septicemia
Completed NCT00794703 - A Study to Compare Efficacy and Safety of Mycamine® and Itraconazole for Preventing Fungal Infections Phase 3
Completed NCT00001937 - Comparing the Effectiveness of Fluconazole and a New Medicine (FK463) in Preventing Fungal Infections in Bone Marrow Transplant Patients Phase 3
Recruiting NCT01260974 - Caspofungin as Prophylaxis in High Risk Liver Transplantation Recipients Phase 2
Recruiting NCT04368559 - Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation Phase 3
Completed NCT01236261 - Prospective Population Study on Candidemia in Spain N/A
Active, not recruiting NCT02743585 - Impact of Rapid Pathogen Identification From Blood Cultures (RABbIT) N/A
Completed NCT02734862 - CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension Phase 2
Completed NCT02719769 - Clinical Performance of the Accelerate ID/AST System for Positive Blood Culture N/A
Completed NCT01450358 - Evaluation in the Treatment of Nosocomial Sepsis Comparing Polymerase Chain Reaction With Conventional Blood Culture. Phase 4
Completed NCT00841971 - Anidulafungin Versus Fluconazole for the Prevention of Fungal Infections in Liver Transplant Recipients Phase 4
Completed NCT01898208 - Rapid Identification and Susceptibility Testing of Pathogens From Blood Cultures N/A
Terminated NCT00806351 - An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Serious Fungal Infection Due To Candida In Patients With A Dysfunctional Immune System Phase 3
Terminated NCT00805740 - An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Deep Tissue Infection Due To Candida Phase 3
Unknown status NCT00460330 - Evaluate Three Methods for Diagnosis of Invasive Fungal Infection in Chinese Patients After HSCT N/A
Completed NCT00001810 - An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections Phase 3